The MEK1/2 Pathway as a Therapeutic Target in High-Grade Serous Ovarian Carcinoma
Mikhail S. Chesnokov(University of Minnesota), Ilana Chefetz(Mercer University)
Cited by 29
Related Papers
Optimized Transcriptional Signature for Evaluation of MEK/ERK Pathway Baseline Activity and Long-Term Modulations in Ovarian Cancer
|International Journal of Molecular Sciences|2022|11
Optimized transcriptional signature for evaluation of MEK/ERK pathway baseline activity and long-term modulations in ovarian cancer
|bioRxiv (Cold Spring Harbor Laboratory)|2022|1